Ceftobiprole medocaril.
Rev Esp Quimioter
; 35 Suppl 1: 25-27, 2022 Apr.
Article
en En
| MEDLINE
| ID: mdl-35488820
ABSTRACT
Ceftobiprole medocaril is a broad-spectrum 5th-generation cephalosporin with activity against Gram-positives such as methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae, and against Gram-negatives such as Pseudomonas aeruginosa. The recommended dose is 500 mg every 8 h in 2-hour infusions. Various clinical trials have demonstrated its usefulness in the treatment of community-acquired pneumonia and nosocomial pneumonia, with the exception of ventilator-associated pneumonia. In summary, it is a very useful antibiotic for the treatment of pneumonia.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Infecciones Comunitarias Adquiridas
/
Staphylococcus aureus Resistente a Meticilina
Límite:
Humans
Idioma:
En
Revista:
Rev Esp Quimioter
Asunto de la revista:
TERAPIA POR MEDICAMENTOS
Año:
2022
Tipo del documento:
Article